Insider Trades: 14 ASX 200 directors bought and sold these stocks last week
Major shareholders from Domino's and GQG Partners bought more stock, while C-suite executives from CBA, South32 and more sold shares.
Source: Shutterstock
Mentioned
Welcome back to the Insider Trades series – a weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The below trades have all taken place between 29 August and 3 September 2025. Directors have up to 5 business days to notify the ASX of their trades.
The volume of director transactions is picking up as reporting season blackout periods lift, and it’s always interesting to see that the lion’s share of sales typically come from CEOs and other C-suite executives.
Top ASX 200 Insider Buys
Ticker | Company | Date | Director | Price | Value |
|---|---|---|---|---|---|
Domino's Pizza | 29/08/25 | $15.11 | $5,061,850 | ||
GQG Partners | 29/08/25 | $1.76 | $477,164 | ||
Regis Healthcare | 29/08/25 | $7.75 | $170,588 | ||
EVT | 29/08/25 | $14.04 | $140,409 | ||
Medibank Private | 1/09/25 | $5.09 | $30,031 | ||
QUBE Holdings | 29/08/25 | $4.16 | $20,800 | ||
Dexus | 29/08/25 | $7.51 | $20,015 | ||
EVT | 2/09/25 | $13.71 | $13,708 |
Key takeaways
Domino’s Pizza: Non-Executive Chairman Jack Cowin purchased 335,000 shares (~$5m), lifting his stake by just 1.3% to a massive 24.5 million shares. Cowin, also founder of Competitive Foods Australia (the Burger King master franchisee in Australia), is buying at an interesting time, with Domino’s trading at levels last seen in late 2013. The stock tumbled 22% on its FY25 result (27 Aug) after a weaker-than-expected trading update and limited cost-saving commentary. While headline numbers were in line, analysts flagged slowing sales momentum, rising leverage, and subdued franchisee profitability as key concerns.
GQG Partners: Chief Investment Officer Rajiv Jain added 270,000 shares (~$477k), a small lift of just 0.01% to his already huge 2.0 billion shareholding. GQG shares are near their lowest since Jan 2024. The latest 1H25 result (announced 24 Aug) was broadly in-line, with market expectations, as stronger performance fees and other income offset softer management fees. FUM rose on solid inflows, but July brought a meaningful institutional outflow, highlighting concentration risk. Analysts noted weaker relative fund performance, due to underweight exposure to tech/AI, leaves wholesale flows more vulnerable near-term, while institutional and sub-advisory channels remain steadier.
Regis Healthcare: The Non-Executive Chairman purchased shares after FY25 results came in ahead of expectations, with both revenue and earnings exceeding consensus. Regis also outlined a target of 10,000 beds by FY28, well above RBC’s forecast of ~7,950. The stock was volatile on results day, rallying as much as 8.3% before closing just 1.2% higher.
Top ASX 200 Insider Sells
Ticker | Company | Date | Director | Price | Value |
|---|---|---|---|---|---|
Stockland | 29/08/25 | $6.20 | $2,902,170 | ||
Harvey Norman | 1/09/25 | $7.35 | $1,837,925 | ||
Commonwealth Bank | 1/09/25 | $169.82 | $1,488,130 | ||
South32 | 1/09/25 | $2.68 | $533,566 | ||
Cochlear | 2/09/25 | $300.01 | $254,708 | ||
Cleanaway Waste | 29/08/25 | $2.82 | $160,745 | ||
Region Group | 3/09/25 | $2.42 | $90,316 |
Key takeaways
Harvey Norman (HVN): CFO Chris Mentis made his first sale since 2018, just as the stock hit record highs following a standout FY25 result. Shares jumped 11.4% on results day (29 Aug) and another 8.5% the next, now trading on 17.8x P/E or the highest multiple since 2015. The beat was driven by strong Australian franchising operations, with Asia and Ireland also contributing, partly offset by UK start-up costs. A strong July update showed Harvey Norman outpacing JB Hi-Fi and The Good Guys for the first time in years, prompting brokers to lift targets and flagging potential for a rerating given valuation discounts to JB Hi-Fi.
Commonwealth Bank (CBA): CEO Matthew Comyn continued his usual pattern of selling ~$1.5–4.0m worth of shares around August/September, consistent with the past three years.
South32 (S32): CEO Graham Kerr offloaded ~6% of his holdings after the company’s FY25 NPAT came in slightly below expectations. The bigger drag was FY26 Worsley unit cost guidance, which rose year-on-year and above analyst forecasts. Macquarie downgraded to Neutral, citing weaker near-term earnings and NAV declines across the portfolio.
Cochlear (COH): CEO Dig Howitt sold a small parcel after a soft FY25 result, with NPAT at the low end of downgraded guidance. FY26 NPAT guidance also missed and was weighted to the second half. Interestingly, Citi stuck with a Buy and even raised its target to $350 (from $300), pointing to a major new product launch cycle from mid-2025 expected to drive 14% EPS CAGR through FY25–28e.
